Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 17th

    Business Editors/Health/Medical Writers
    Roth Capital Partners 17th Annual Growth Stock Conference

    PHOENIX--(BUSINESS WIRE)--Feb. 15, 2005--Matrixx Initiatives, Inc. (Nasdaq:MTXX) will be presenting on February 22, 2005, at the Roth Capital Partners 17th Annual Growth Stock Conference at the St. Regis Monarch Beach Resort in Dana Point, California. During the presentation the Company will outline expectations for 2005.
    The Company will be presenting at 1:00 p.m. PT. To listen to the live presentation please visit www.matrixxinc.com. Interested parties should login 15 minutes prior to the event to register and to install Windows Media Player if necessary. A replay of the presentation will be archived at the same web site address for 30 days.

    About Matrixx Initiatives, Inc.

    Matrixx Initiatives, Inc. is a rapidly growing innovator in the development, manufacture and marketing of over-the-counter (OTC) pharmaceuticals, which utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells Zicam(R) Cold Remedy nasal gel, a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam(R) brand pharmaceuticals, including Zicam Cold Remedy Chewables(TM); Zicam Cold Remedy Oral Mist(TM); and Zicam Cold Remedy RapidMelts(TM); Zicam Allergy Relief; Zicam Cold Remedy Swabs(TM); Zicam Kids Size Cold Remedy Swabs(TM); Zicam Extreme Congestion Relief; Zicam Sinus Relief; and Zicam Nasal Moisturizer. Additionally, in July 2004 Matrixx began distributing six new Cough Mist(TM) products for the 2004-2005 cough/cold season. For more information regarding Matrixx products, go to www.zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq:MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, chief financial officer, 602-385-8888, whemelt@matrixxinc.com, or Bill Barba, investor relations, at 602-385-8881, bbarba@matrixxinc.com. Matrixx is located at 4742 N. 24th Street, Suite 455, Phoenix, Arizona 85016.

    About the Roth Capital Partners 17th Annual Growth Stock Conference

    This conference will feature more than 220 leading growth companies in sectors such as Technology, Healthcare, Financial Services and Consumer Products. A concentrated, two-day program will allow institutional investors to meet the executives from a select group of companies that have been hand picked by the Roth Capital Partners research team. 40% of this year's participating companies are presenting here for the first time. The average market cap of this year's presenters is around $330 million, with the median around $185 million. This closely mirrors the average and median market cap for the proposed Russell Microcap(TM) Index which is expected to be around $277 million and $176 million, respectively.
    To register for this conference, please contact your Roth sales representative at 800-678-9147. Please note that this conference is by invitation only.
    For more information about the conference visit: http://www.rothcp.com/2005%20DP%20Conference%20Web%20Site/ Roth%20DP.html?content=home (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

--30--MTB/la*

CONTACT: Matrixx Initiatives, Inc. William Hemelt, 602-385-8888 whemelt@matrixxinc.com Bill Barba, 602-385-8881 (Investor Relations) bbarba@matrixxinc.com

KEYWORD: CALIFORNIA ARIZONA INDUSTRY KEYWORD: PHARMACEUTICAL TRADESHOW CONFERENCE CALLS SOURCE: Matrixx Initiatives, Inc.

Copyright Business Wire 2005